EMSY

Across TCGA pan-cancer cohorts, EMSY Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EMSY data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EMSY Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EMSY expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUAD, SKCM, and UCEC are the cancer types where EMSY Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.373	0.700	.026	6	view →
SKCM	DFS	Median	All	0.229	0.640	.032	6	view →
UCEC	DFS	Median	All	0.745	0.635	.036	4	view →
BLCA	OS	Median	IV	0.141	0.573	.034	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	OS	Median	II,III,IV	0.225	0.615	.041	3	view →
STAD	DFS	Median	All	1.000	0.383	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EMSY–LUAD (OS)

Open the LUAD breakdown →